

.jpg)
Many of the men I work with take their health seriously. They’ve built good routines and track their sleep, nutrition, and training, and their goal is to stay sharp and strong in the gym and everywhere else. It’s no surprise that many are looking for their next breakthrough, and peptides have gone from group chat chatter, to serious topics for patients and clinicians.
For many men exploring peptides, peak performance means getting the most out of both their body and mind. In a recent survey commissioned by Hims & Hers of 2,000 adults in the U.S., including 1,000 men, nearly half of the men (49%) said they’d want a peptide offering to support strength, and 37% said they’d hope a peptide could give them more energy. The goal isn’t just physical. Two-thirds of those surveyed said staying mentally sharp matters more to them than staying physically fit.¹ For performance-focused individuals who want the best of both, peptides can offer a way to support the body and brain at a cellular level.
Too often, getting them has meant relying on unreliable and unregulated online sellers, with little way to know what you’re getting. That changes today. Hims is launching Peptides+, a clinically-guided specialty that offers eligible men access to five treatments to start, built around their individual biology.
{inline-gallery}
Peptides are short chains of amino acids that cells use to send signals to one another. The Peptides+ specialty includes peptides and other well-known compounds the body relies on to provide support for cellular energy and repair. The compounded treatments in Peptides+ contain the below active ingredients:
A customer’s experience starts with an intake covering his health history, current medications and goals. An independent, licensed provider trained in peptide therapies then decides whether he’s eligible and which treatment, if any, makes sense for him. Treatments are compounded in the U.S. and dispensed by U.S. licensed pharmacies.
Peptides+ is available with Care+, which pairs treatment with a comprehensive insights and support experience. Customers have access to lab testing twice a year to track their progress, unlimited support and ongoing check-ins from a dedicated Care Team, and the option to message providers trained in peptide therapy 24/7 with any questions. To give customers and their providers a baseline from day one, without an office visit, the Hims Men’s Core Panel is an at-home blood collection kit for lab testing that provides insights across 22 biomarkers, including testosterone, vitamin D, and cholesterol. For those whose lab results indicate potential eligibility, Care+ customers can also connect with a provider to determine if a testosterone treatment may be right for them.
Proactive men are always looking for what’s next, and Peptides+ is built for them. Alongside sleep, training, nutrition, and regular check-ins with a provider, it’s another way to pursue what peak performance can be, both physically and cognitively. As curiosity about peptides grows, Hims & Hers is meeting it with clarity, and we’re excited to help shape the future of proactive health, with the clinical rigor that men deserve.
Hims & Hers plans to add more peptides and therapies to this specialty, and looks forward to offering BPC-157 and TB-500 consistent with regulatory standards.
1Based on an online survey of 2,009 U.S. adults ages 18 and older, including 1,007 women and 1,002 men, commissioned by Hims & Hers and conducted in October 2026. Respondents were 50% women (n=1,007) and 50% men (n=1,002). By age: 18–30, 22% (n=439); 31–45, 26% (n=514); 46–59, 23% (n=466); 60+, 29% (n=590). Participation was voluntary. Some figures reflect subgroups of respondents. Results may not be representative of all Americans.
Cautionary Note Regarding Forward-Looking Statements
This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “anticipates,” “expects,” “intends,” “plans,” “decides,” “may,” “will,” “likely,” “potential,” “future,” “over time,” “coming,” “hope,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the launch and availability of Peptides+, including the treatments available at launch and their potential benefits; our plans to add additional peptides and therapies, including BPC-157 and TB-500, consistent with regulatory standards; the availability and expected benefits of Care+ and related lab testing and support offerings; and the potential effects of Peptides+ on our customers and our business. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to the rollout of Peptides+ and the addition of new peptides and therapies, and the related customer response; the supply chain for the Peptides+ offering; the evolving clinical evidence and regulatory status of the peptide therapies we offer or plan to offer, and our ability to offer such therapies consistent with regulatory standards; other changes in the application, interpretation, and enforcement of healthcare, pharmacy, compounding, consumer protection, or privacy laws or regulations applicable to our business in the United States; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of November 18, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.